Researchers announced promising results from a large clinical trial testing an experimental pancreatic cancer drug called daraxonrasib. The study involved 500 patients with metastatic pancreatic cancer whose disease had stopped responding to previous treatments, a group that typically has very limited options.

Patients who received the daily pill lived a median of 13.2 months, compared with 6.7 months for those who received additional chemotherapy. The findings were published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology’s annual meeting in Chicago.

The drug targets KRAS, a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases. Scientists have spent decades developing treatments against KRAS, which was long considered one of the most difficult targets in cancer research.

Researchers also reported that patients taking daraxonrasib experienced less pain, fewer severe side effects, and a better quality of life than those receiving chemotherapy. Many participants remained on the treatment after the study data were analyzed, raising the possibility that the survival gap could widen over time.

Pancreatic cancer remains one of the deadliest forms of cancer. The disease is notoriously difficult to detect before it spreads, and treatment options have historically lagged behind those available for many other cancers. According to the American Cancer Society, more than 52,000 Americans are expected to die from pancreatic cancer this year.

He recommended Nvidia in 2016 for the chance at a 1,466% gain... Rocket Lab at $5.37 — before it soared past $69... And just weeks ago, he closed a 357% gain on Globalstar after Amazon stepped in to buy the company. This Thursday, Stansberry Research’s in-house space expert will name a tiny, virtually unknown company that he believes will be his next 1,000% winner as the SpaceX IPO unfolds. See the full details here.

What makes the results of this new experimental pill is not just the increase in survival time, but the fact that the drug outperformed chemotherapy in a patient population with few remaining options. Several cancer specialists described the findings as one of the most important advances in pancreatic cancer treatment in years.

The trial also marks a milestone in efforts to target KRAS mutations. For decades, researchers struggled to develop drugs that could bind effectively to the protein. Daraxonrasib uses a different approach that allows it to attach to multiple KRAS subtypes, potentially expanding its usefulness across a wide range of patients.

The results are generating optimism beyond this single treatment, and researchers are already studying whether the drug can be used earlier in the disease process and whether tumor shrinkage could make more patients eligible for surgery.

For patients facing pancreatic cancer, the findings offer a treatment option that could soon become available if federal regulators approve the drug. The Food and Drug Administration has already indicated it will expedite its review, and some eligible patients may be able to access the treatment through expanded access programs before full approval.

The study may also influence how doctors approach pancreatic cancer treatment in the future. If approved, daraxonrasib could replace chemotherapy as the standard second-line treatment for many patients whose cancer has progressed after initial therapy.

The drug's success could have implications beyond pancreatic cancer because KRAS mutations are also found in several other major cancers, including lung and colorectal cancer. Researchers have spent decades trying to effectively target these mutations, making KRAS one of the most sought-after targets in cancer research.

While daraxonrasib is still being studied, the trial offers fresh evidence that drugs aimed at KRAS can produce promising results, potentially opening the door to new treatments for a much larger population of cancer patients in the future.